CL2017000829A1 - Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. - Google Patents
Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.Info
- Publication number
- CL2017000829A1 CL2017000829A1 CL2017000829A CL2017000829A CL2017000829A1 CL 2017000829 A1 CL2017000829 A1 CL 2017000829A1 CL 2017000829 A CL2017000829 A CL 2017000829A CL 2017000829 A CL2017000829 A CL 2017000829A CL 2017000829 A1 CL2017000829 A1 CL 2017000829A1
- Authority
- CL
- Chile
- Prior art keywords
- formulation
- citrate
- antibody
- mixture
- inflammatory bowel
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 1
- 239000006172 buffering agent Substances 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
<p>UNA FORMULACIÓN FARMACÉUTICA LIQUIDA ESTABLE, QUE COMPRENDE AL MENOS ALREDEDOR DE 60 MG/ML A ALREDEDOR DE 160 MG/ML DE ANTICUERPO ANTI-α4β7, UN AGENTE TAMPONANTE Y AL MENOS ALREDEDOR DE 5 MM DE CITRATO, EN DONDE DICHA FORMULACIÓN ES UNA FORMULACIÓN LIQUIDA; USO DE DICHA FORMULACIÓN PARA LA PREPARACIÓN DE UN MEDICAMENTO ÚTIL PARA TRATAR LA ENFERMEDAD INFLAMATORIA DEL INTESTINO EN UN SUJETO.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161481522P | 2011-05-02 | 2011-05-02 | |
US201161544054P | 2011-10-06 | 2011-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017000829A1 true CL2017000829A1 (es) | 2017-12-29 |
Family
ID=46147702
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003145A CL2013003145A1 (es) | 2011-05-02 | 2013-10-30 | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre. |
CL2017000829A CL2017000829A1 (es) | 2011-05-02 | 2017-04-05 | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. |
CL2020001579A CL2020001579A1 (es) | 2011-05-02 | 2020-06-12 | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003145A CL2013003145A1 (es) | 2011-05-02 | 2013-10-30 | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020001579A CL2020001579A1 (es) | 2011-05-02 | 2020-06-12 | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145) |
Country Status (37)
Country | Link |
---|---|
US (6) | US10040855B2 (es) |
EP (2) | EP2704742B1 (es) |
JP (5) | JP6190359B2 (es) |
KR (7) | KR20230021758A (es) |
CN (4) | CN108969469A (es) |
AR (1) | AR086238A1 (es) |
AU (5) | AU2012250872B2 (es) |
CA (2) | CA3051418C (es) |
CL (3) | CL2013003145A1 (es) |
CO (1) | CO6801648A2 (es) |
CR (1) | CR20130556A (es) |
CY (1) | CY1119436T1 (es) |
DK (1) | DK2704742T3 (es) |
DO (1) | DOP2013000252A (es) |
EA (1) | EA032625B1 (es) |
EC (1) | ECSP22046340A (es) |
ES (1) | ES2646717T3 (es) |
GE (1) | GEP20186866B (es) |
HK (1) | HK1253911A1 (es) |
HR (1) | HRP20171457T1 (es) |
HU (1) | HUE036664T2 (es) |
IL (6) | IL305583A (es) |
LT (1) | LT2704742T (es) |
ME (1) | ME02858B (es) |
MX (4) | MX354101B (es) |
MY (1) | MY188820A (es) |
PE (1) | PE20141672A1 (es) |
PH (2) | PH12018502221A1 (es) |
PL (1) | PL2704742T3 (es) |
PT (1) | PT2704742T (es) |
RS (1) | RS56429B1 (es) |
SG (1) | SG194730A1 (es) |
SI (1) | SI2704742T1 (es) |
TW (4) | TWI638661B (es) |
UY (1) | UY34054A (es) |
WO (1) | WO2012151247A2 (es) |
ZA (2) | ZA201308168B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2688093T3 (es) | 2010-01-06 | 2018-10-30 | Dyax Corp. | Proteínas de unión a calicreína plasmática |
JP5918246B2 (ja) * | 2010-10-06 | 2016-05-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤 |
EP2661450A4 (en) | 2011-01-06 | 2014-04-23 | Dyax Corp | PROTEINS BINDING TO PLASMA KALLIKREINE |
CN108969469A (zh) | 2011-05-02 | 2018-12-11 | 米伦纽姆医药公司 | 抗α4β7抗体的制剂 |
SG10201605516YA (en) | 2011-07-06 | 2016-08-30 | Nestec Sa | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
US9764093B2 (en) * | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
AU2014240045A1 (en) | 2013-03-15 | 2015-09-10 | Dyax Corp. | Anti-plasma kallikrein antibodies |
NZ715667A (en) * | 2013-07-05 | 2022-02-25 | Stellar Biome Inc | Oral compositions |
EP3073992A4 (en) * | 2013-11-29 | 2017-09-13 | Ares Trading S.A. | A liquid formulation of a fusion protein comprising tnfr and fc region |
SG11201702793XA (en) | 2014-10-06 | 2017-05-30 | Chemocentryx Inc | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
JP2017537105A (ja) | 2014-11-26 | 2017-12-14 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 瘻孔を伴うクローン病の治療用ベドリズマブ |
EP3763384A1 (en) * | 2014-12-03 | 2021-01-13 | CSL Behring AG | Pharmaceutical product with increased stability comprising immunoglobulins |
JP2018500553A (ja) * | 2014-12-05 | 2018-01-11 | ネステク ソシエテ アノニム | 患者試料における生物製剤の検出のための間接的均一移動度シフトアッセイ |
JP6904905B2 (ja) | 2014-12-24 | 2021-07-21 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 抗α4β7インテグリン抗体による治療の結果の予測 |
MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
AU2016243160B2 (en) * | 2015-03-30 | 2022-02-24 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
WO2017031151A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
CA2994447A1 (en) | 2015-12-11 | 2017-06-15 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
AU2016380988B2 (en) * | 2015-12-30 | 2022-07-21 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
USD866757S1 (en) | 2016-03-11 | 2019-11-12 | Millennium Pharmaceuticals, Inc. | Autoinjector |
CN109153721A (zh) | 2016-03-14 | 2019-01-04 | 千禧制药公司 | 治疗或预防移植物抗宿主疾病的方法 |
US20200002422A1 (en) * | 2016-03-14 | 2020-01-02 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
MA44864A (fr) | 2016-05-04 | 2019-03-13 | Icahn School Med Mount Sinai | Trithérapie pour le traitement d'une maladie intestinale inflammatoire |
MA45245A (fr) * | 2016-06-12 | 2019-04-17 | Millennium Pharm Inc | Méthode de traitement de maladie intestinale inflammatoire |
JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
CR20190291A (es) * | 2016-12-23 | 2019-11-05 | Serum Institute Of India Pvt Ltd | Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos |
CN108686204A (zh) * | 2017-04-07 | 2018-10-23 | 浙江海正药业股份有限公司 | 包含组氨酸缓冲体系的英夫利西单抗组合物 |
KR20190141148A (ko) * | 2017-04-28 | 2019-12-23 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 소아 장애를 치료하는 방법 |
AU2018322032A1 (en) * | 2017-08-25 | 2020-03-12 | Omeros Corporation | Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome |
SG11202009876TA (en) * | 2018-04-10 | 2020-11-27 | Dr Reddy’s Laboratories Ltd | Stable formulations of therapeutic antibody |
JP2021521168A (ja) * | 2018-04-10 | 2021-08-26 | ドクター レディズ ラボラトリーズ リミテッド | 安定な抗体製剤 |
EP3773694A4 (en) * | 2018-04-10 | 2021-12-29 | Dr. Reddy's Laboratories Ltd. | Antibody formulation |
EP3843783A1 (en) * | 2018-08-29 | 2021-07-07 | GlaxoSmithKline Intellectual Property Development Limited | Methods of preparing stable liquid therapeutic protein compositions |
BR112021015034A2 (pt) | 2019-02-18 | 2021-10-05 | Eli Lilly And Company | Formulação de anticorpo terapêutico |
AU2020290999A1 (en) * | 2019-06-10 | 2022-02-03 | Takeda Pharmaceutical Company Limited | Antibody purification methods and compositions thereof |
JP2022551622A (ja) * | 2019-10-11 | 2022-12-12 | ドクター レディズ ラボラトリーズ リミテッド | インテグリン抗体の安定な製剤 |
WO2022026699A1 (en) * | 2020-07-31 | 2022-02-03 | Genentech, Inc. | Anti-integrin beta7 antibody formulations and devices |
US20240101679A1 (en) * | 2020-12-09 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Stable aqueous buffer free formulation of an integrin antibody |
WO2022253994A1 (en) * | 2021-06-04 | 2022-12-08 | Polpharma Biologics S.A. | Vedolizumab formulation |
CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
WO2023126411A1 (en) | 2021-12-27 | 2023-07-06 | Polpharma Biologics S.A. | Vedolizumab formulation |
WO2023230620A1 (en) * | 2022-05-27 | 2023-11-30 | Sonnet BioTherapeutics, Inc. | Il-12-albumin-binding domain fusion protein formulations and methods of use thereof |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5403919A (en) | 1987-08-11 | 1995-04-04 | Board Of Trustees Of The Leland Stanford Junior University Stanford University | Method to control leukocyte extravasation |
US5538724A (en) | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
ATE114478T1 (de) | 1987-08-11 | 1994-12-15 | Univ Leland Stanford Junior | Verfahren zur kontrolle der leukozyten- extravasation. |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5223392A (en) | 1988-01-25 | 1993-06-29 | Exocell, Inc. | Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
EP0462111A4 (en) | 1988-12-23 | 1992-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Homing sequences and their uses |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
IL113261A (en) | 1989-09-01 | 1996-10-16 | Hutchinson Fred Cancer Res | Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing |
US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP1362868A3 (en) | 1991-03-06 | 2004-02-11 | MERCK PATENT GmbH | Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R) |
US5665595A (en) | 1991-06-07 | 1997-09-09 | Dowelanco | Immunoglobulins against insect tissue |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
AU674302B2 (en) | 1992-02-12 | 1996-12-19 | Biogen Idec Ma Inc. | Treatment for inflammatory bowel disease |
AU4390893A (en) | 1992-05-21 | 1993-12-13 | Center For Blood Research, Inc., The | A novel receptor for alpha4 integrins and methods based thereon |
WO1994012214A1 (en) | 1992-12-01 | 1994-06-09 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
WO1994013312A1 (en) | 1992-12-15 | 1994-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
WO1994016094A2 (en) | 1993-01-12 | 1994-07-21 | Biogen, Inc. | Recombinant anti-vla4 antibody molecules |
ES2114183T5 (es) | 1993-02-09 | 2006-06-16 | Biogen Idec Ma, Inc. | Anticuerpo para el tratamiento de la diabetes dependiente de la insulina. |
US6017695A (en) | 1993-03-26 | 2000-01-25 | Becton Dickinson And Company | Nucleic acids encoding human cell adhesion molecule |
JPH06303990A (ja) | 1993-04-24 | 1994-11-01 | Kanebo Ltd | モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法 |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
KR100367948B1 (ko) | 1994-01-25 | 2003-07-12 | 엘란 파마슈티칼스, 인크. | 백혈구부착분자vla-4에대한인체화된항체 |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US5594120A (en) | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
US5610281A (en) | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
US5624321A (en) | 1994-12-23 | 1997-04-29 | Snyder; Stephen D. | Spring-actuated swing device |
CA2212702C (en) | 1995-02-10 | 2010-04-20 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
BR0307975A (pt) | 2002-02-25 | 2005-01-11 | Elan Pharm Inc | Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina |
WO2003099773A1 (en) | 2002-05-24 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
ATE517102T1 (de) | 2002-11-18 | 2011-08-15 | Chemocentryx Inc | Arylsulfonamide |
WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
CN100353997C (zh) | 2003-02-28 | 2007-12-12 | 中外制药株式会社 | 稳定的含蛋白质的制剂 |
JP4869064B2 (ja) | 2003-04-04 | 2012-02-01 | ジェネンテック, インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
RU2453558C2 (ru) | 2004-09-03 | 2012-06-20 | Дженентек, Инк. | Гуманизированные антагонистические антитела против бета7 и их применение |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
WO2006096488A2 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising human igg2 antibody and chelating agent |
WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
CA2629147A1 (en) * | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin |
WO2007092772A2 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
CN101426527A (zh) * | 2006-02-03 | 2009-05-06 | 米迪缪尼有限公司 | 蛋白质制剂 |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
MEP39508A (en) | 2006-04-21 | 2011-02-10 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
US9193790B2 (en) | 2006-12-07 | 2015-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of antagonists of the interaction between HIV GP120 and A4B7 integrin |
EP2094729A1 (en) | 2006-12-11 | 2009-09-02 | F.Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
EP2205145A4 (en) | 2007-07-06 | 2013-06-19 | Stereotaxis Inc | MANAGEMENT OF A MEDICAL LIVE REMOTE DISPLAY |
UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
AU2008334605B2 (en) * | 2007-12-13 | 2013-07-18 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
EP2408816B1 (en) * | 2009-03-20 | 2019-09-04 | Amgen Inc. | Alpha-4-beta-7 heterodimer specific antagonist antibody |
CN101533504A (zh) * | 2009-04-27 | 2009-09-16 | 刘文祥 | 电子医务系统及其装置 |
RU2012139181A (ru) | 2010-02-26 | 2014-04-10 | Ново Нордиск А/С | Стабильная композиция, содержащая антитело |
CN108969469A (zh) * | 2011-05-02 | 2018-12-11 | 米伦纽姆医药公司 | 抗α4β7抗体的制剂 |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
-
2012
- 2012-05-02 CN CN201810453958.4A patent/CN108969469A/zh active Pending
- 2012-05-02 AU AU2012250872A patent/AU2012250872B2/en active Active
- 2012-05-02 KR KR1020237002891A patent/KR20230021758A/ko not_active Application Discontinuation
- 2012-05-02 EP EP12722973.0A patent/EP2704742B1/en not_active Revoked
- 2012-05-02 KR KR1020187018702A patent/KR102014512B1/ko active IP Right Grant
- 2012-05-02 WO PCT/US2012/036069 patent/WO2012151247A2/en active Application Filing
- 2012-05-02 UY UY0001034054A patent/UY34054A/es not_active Application Discontinuation
- 2012-05-02 KR KR1020177012979A patent/KR101884406B1/ko active IP Right Grant
- 2012-05-02 CN CN201711133991.0A patent/CN107998388B/zh active Active
- 2012-05-02 PT PT127229730T patent/PT2704742T/pt unknown
- 2012-05-02 RS RS20171015A patent/RS56429B1/sr unknown
- 2012-05-02 CA CA3051418A patent/CA3051418C/en active Active
- 2012-05-02 CA CA2834900A patent/CA2834900C/en active Active
- 2012-05-02 GE GEAP201213302A patent/GEP20186866B/en unknown
- 2012-05-02 ES ES12722973.0T patent/ES2646717T3/es active Active
- 2012-05-02 LT LTEP12722973.0T patent/LT2704742T/lt unknown
- 2012-05-02 TW TW101115710A patent/TWI638661B/zh active
- 2012-05-02 SG SG2013080940A patent/SG194730A1/en unknown
- 2012-05-02 SI SI201231076T patent/SI2704742T1/sl unknown
- 2012-05-02 TW TW106123969A patent/TWI698254B/zh active
- 2012-05-02 TW TW108104506A patent/TWI723339B/zh active
- 2012-05-02 DK DK12722973.0T patent/DK2704742T3/en active
- 2012-05-02 KR KR1020217031194A patent/KR102493433B1/ko active IP Right Review Request
- 2012-05-02 MX MX2013012725A patent/MX354101B/es active IP Right Grant
- 2012-05-02 KR KR1020137031205A patent/KR101875155B1/ko active IP Right Grant
- 2012-05-02 US US14/114,835 patent/US10040855B2/en active Active
- 2012-05-02 EP EP17180247.3A patent/EP3311834A1/en active Pending
- 2012-05-02 CN CN201280021789.8A patent/CN103533959B/zh active Active
- 2012-05-02 EA EA201391613A patent/EA032625B1/ru not_active IP Right Cessation
- 2012-05-02 KR KR1020207020503A patent/KR102308938B1/ko active IP Right Grant
- 2012-05-02 PE PE2013002433A patent/PE20141672A1/es active IP Right Grant
- 2012-05-02 MX MX2017007134A patent/MX367097B/es unknown
- 2012-05-02 CN CN201810453956.5A patent/CN108969761A/zh active Pending
- 2012-05-02 MY MYPI2013003974A patent/MY188820A/en unknown
- 2012-05-02 KR KR1020197024347A patent/KR102136208B1/ko active IP Right Grant
- 2012-05-02 HU HUE12722973A patent/HUE036664T2/hu unknown
- 2012-05-02 AR ARP120101540A patent/AR086238A1/es not_active Application Discontinuation
- 2012-05-02 PL PL12722973T patent/PL2704742T3/pl unknown
- 2012-05-02 JP JP2014509377A patent/JP6190359B2/ja active Active
- 2012-05-02 ME MEP-2017-227A patent/ME02858B/me unknown
- 2012-05-02 IL IL305583A patent/IL305583A/en unknown
- 2012-05-02 TW TW109140548A patent/TWI799757B/zh active
-
2013
- 2013-10-29 DO DO2013000252A patent/DOP2013000252A/es unknown
- 2013-10-29 CR CR20130556A patent/CR20130556A/es unknown
- 2013-10-30 CL CL2013003145A patent/CL2013003145A1/es unknown
- 2013-10-31 IL IL229169A patent/IL229169B/en active IP Right Grant
- 2013-10-31 MX MX2021008112A patent/MX2021008112A/es unknown
- 2013-10-31 MX MX2019009244A patent/MX2019009244A/es unknown
- 2013-10-31 ZA ZA2013/08168A patent/ZA201308168B/en unknown
- 2013-11-01 CO CO13259852A patent/CO6801648A2/es unknown
-
2017
- 2017-04-05 CL CL2017000829A patent/CL2017000829A1/es unknown
- 2017-05-10 JP JP2017094129A patent/JP6467457B2/ja active Active
- 2017-06-21 AU AU2017204192A patent/AU2017204192B2/en active Active
- 2017-09-28 HR HRP20171457TT patent/HRP20171457T1/hr unknown
- 2017-10-11 CY CY20171101057T patent/CY1119436T1/el unknown
- 2017-10-27 ZA ZA2017/07310A patent/ZA201707310B/en unknown
-
2018
- 2018-05-18 US US15/983,791 patent/US20180327497A1/en not_active Abandoned
- 2018-06-15 US US16/009,865 patent/US20180346578A1/en not_active Abandoned
- 2018-10-12 HK HK18113059.1A patent/HK1253911A1/zh unknown
- 2018-10-17 PH PH12018502221A patent/PH12018502221A1/en unknown
-
2019
- 2019-01-11 JP JP2019003265A patent/JP6751450B2/ja active Active
- 2019-07-17 PH PH12019501662A patent/PH12019501662A1/en unknown
- 2019-08-15 AU AU2019216679A patent/AU2019216679B2/en active Active
-
2020
- 2020-01-26 IL IL272237A patent/IL272237B/en unknown
- 2020-02-11 US US16/787,521 patent/US11560434B2/en active Active
- 2020-05-21 IL IL274846A patent/IL274846A/en unknown
- 2020-06-12 CL CL2020001579A patent/CL2020001579A1/es unknown
- 2020-08-14 JP JP2020136927A patent/JP7107997B2/ja active Active
-
2021
- 2021-04-23 US US17/239,512 patent/US20210340261A1/en active Pending
- 2021-08-31 AU AU2021225160A patent/AU2021225160B2/en active Active
-
2022
- 2022-02-23 IL IL290849A patent/IL290849A/en unknown
- 2022-02-23 IL IL290848A patent/IL290848A/en unknown
- 2022-06-10 EC ECSENADI202246340A patent/ECSP22046340A/es unknown
- 2022-07-14 JP JP2022112814A patent/JP2022132430A/ja active Pending
- 2022-10-13 US US18/046,450 patent/US20230312727A1/en active Pending
-
2023
- 2023-12-04 AU AU2023274233A patent/AU2023274233A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017000829A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. | |
CL2017000830A1 (es) | Formulación estable que comprende un azúcar no reductora, un anticuerpo anti-s4b7 y al menos un aminoácido libre; un método para preparar dicha formulación; uso de dicha formulación para tratar una enfermedad inflamatoria del intestino. | |
AR109461A2 (es) | Formulación de anticuerpo anti-cd20 y su uso para preparar un medicamento | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
UY31867A (es) | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 | |
AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
MX2016006896A (es) | Microcapsulas de lipidos que comprenden preferiblemente una substancia activa lipofilica y composicion que las contiene, su metodo de preparacion y su uso en dermatolgia y cosmetica. | |
CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
CL2012000319A1 (es) | Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística. | |
CL2011002248A1 (es) | Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor. | |
CL2016001411A1 (es) | Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina. | |
UA101903C2 (ru) | Лекарственное средство на основе дииндолилметана для лечения гиперпластических и воспалительных заболеваний | |
EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
NI201000189A (es) | Formulación de medicamento sólido con liberación retardadas. | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
EA201590797A1 (ru) | Препараты с модифицированным высвобождением опрозомиба | |
CL2013003630A1 (es) | Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros. | |
PE20150190A1 (es) | Formulacion farmaceutica | |
RU2015109566A (ru) | НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА | |
EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения | |
CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
RU2012129115A (ru) | Способ лечения острых послеродовых эндометритов у коров | |
CL2015001368A1 (es) | Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion "a la carta". | |
MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. |